Tony G. Kleijn

Tony G. Kleijn

Auto-generated profile, based on publicly available information

Tony G. Kleijn

University of Groningen

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

23 January 2025 in Laboratory Investigation
Verified
Journal Article
Open access
TKTony G. Kleijn
Tony G. Kleijn
BABaptiste Ameline
Baptiste Ameline
WSWillem H. Schreuder
Willem H. Schreuder
KSKároly Szuhai
Károly Szuhai
WKWierd Kooistra
Wierd Kooistra
ACArjen H.G. Cleven
Arjen H.G. Cleven
Fibro-osseous tumors of the craniofacial bones are a heterogeneous group of lesions comprising cemento-osseous dysplasia (COD), cemento-ossifying fibroma (COF), juvenile trabecular ossifying fibroma (JTOF), psammomatoid ossifying fibroma (PsOF), fibrous dysplasia (FD), and low-grade osteosarcoma (LGOS) with overlapping clinicopathological features. However, their clinical behavior and treatment differ significantly, underlining the need for accurate diagnosis. Molecular diagnostic markers exist for subsets of these tumors, including GNAS mutations in FD, SATB2 fusions in PsOF, mutations involving the RAS-MAPK signaling pathway in COD, and MDM2 amplification in LGOS. Because DNA methylation and copy number profiling are well established for the classification of central nervous system tumors, we aimed to investigate whether this tool might be used as well for classifying fibro-osseous tumors in the craniofacial bones. We collected a well-characterized, multicenter cohort with available molecular data, including COD (n = 20), COF (n = 13), JTOF (n = 10), PsOF (n = 25), FD (n = 23), LGOS (n = 4), and high-grade osteosarcoma (HGOS; n = 11). Genome-wide DNA methylation and copy number variation data were generated using the Illumina Infinium Methylation EPIC array interrogating >850 000 CpG sites. DNA methylation profiling yielded evaluable results in 73/106 tumors, including 6 CODs, 12 COFs, 6 JTOFs, 19 PsOFs, 18 FDs, 2 LGOSs, and 10 HGOSs. Unsupervised clustering and dimensionality reduction (Uniform Manifold Approximation and Projection) revealed that FD, extragnatic PsOF, and HGOS formed distinct clusters. Surprisingly, COD, COF, JTOF, and mandibular PsOF clustered together, apart from other craniofacial bone tumors. LGOS did not form a distinct cluster, likely due to the low number of cases. Copy number analysis revealed that FD, COD, COF, JTOF, and PsOF were typically characterized by flat copy number profiles compared with LGOS with gains of chromosome 12 and HGOS with multiple heterogeneous copy number alterations. In conclusion, using DNA methylation and copy number profiles, benign fibro-osseous tumors can be separated from low-grade and HGOSs in the craniofacial bones, which is of diagnostic value in challenging cases with overlapping clinicopathological features.

29 January 2026 in International Journal of Surgical Pathology
Verified
Journal Article
Open access
TKTony G. Kleijn
Tony G. Kleijn
BABaptiste Ameline
Baptiste Ameline
WKWierd Kooistra
Wierd Kooistra
LKLéon van Kempen
Léon van Kempen
GDGilles F.H. Diercks
Gilles F.H. Diercks
ACArjen H.G. Cleven
Arjen H.G. Cleven
Background: Myxofibrosarcoma (MFS) and undifferentiated soft tissue sarcoma (USTS) are common sarcoma subtypes with overlapping molecular features. Both are treated with neoadjuvant radiotherapy followed by surgery, yet radiotherapy response is variable and unpredictable. This study investigated DNA methylation and copy number variation (CNV) profiles obtained from pre-radiotherapy biopsies as predictive biomarkers of radiotherapy response. Patients and methods: Pre-radiotherapy biopsies and post-radiotherapy resections were obtained from 49 patients (27 MFS, 22 USTS). Radiotherapy response was assessed on the resection specimens using the EORTC-STBSG 5-tier system; grades A-C (<10% viable tumor) were classified as responders, D-E (≥10% viable tumor) as non-responders. Genome-wide DNA methylation and CNV data were generated from the pre-radiotherapy biopsies using Illumina MethylationEPIC BeadChips and were correlated with response grades. Results: DNA methylation profiling yielded evaluable results in 23/49 tumors (15 MFS, 8 USTS), with 9 responders and 14 non-responders. Unsupervised methylation clustering, incorporating public datasets, showed that MFS, USTS, and pleomorphic liposarcomas formed a single, heterogeneous cluster. Similarly, CNV profiles did not distinguish MFS from USTS. Methylation patterns did not significantly differ between responders and non-responders. CNV profiles were largely comparable between responders and non-responders, except of a significantly higher frequency of chromosome 11q24.1 loss in responders compared to non-responders (100% vs 33%; P = 0.0039). Conclusions: Our findings support the concept that MFS and USTS represent a spectrum of the same disease. We could not demonstrate the value of DNA methylation profiling in radiotherapy response prediction. However, 11q24.1 loss may represent a potential predictive biomarker and merits further validation.

15 June 2022
Verified
Journal Article
Closed access
TKT G Kleijn
T G Kleijn
ISI Scholten
I Scholten
HKH M Knol
H M Knol
JZJ J Zwart
J J Zwart
AHA M Hoogland
A M Hoogland